Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus PANDEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus PANDEL.
ANUSOL HC vs PANDEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
Pandel (hydrocortisone probutate) is a topical corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins inhibit the release of arachidonic acid from membrane phospholipids, thereby reducing the synthesis of prostaglandins, leukotrienes, and other inflammatory mediators. This results in vasoconstriction, decreased edema, and suppression of the inflammatory and pruritic responses.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
Topical: Apply a thin film to affected skin areas twice daily. Maximum: 15 g per application; not to exceed 60 g per week.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
2-4 hours (terminal); clinical context: requires frequent dosing due to rapid elimination.
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Primarily renal (90% as unchanged drug); biliary/fecal excretion negligible (<5%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid